Your session is about to expire
← Back to Search
eHealth Genetic Testing for Cancer (eReach2 Trial)
eReach2 Trial Summary
This trial will compare the effects of standard genetic counseling to a self-directed web-based intervention.
eReach2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria beloweReach2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.eReach2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I qualify for genetic testing based on national cancer guidelines.I do not have severe mental, physical, or cognitive issues that prevent me from understanding this study.I am either male or female.I have not had genetic testing for inherited conditions.
- Group 1: ARM D
- Group 2: ARM A
- Group 3: ARM B
- Group 4: ARM C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this experimentation still open?
"Affirmative, according to clinicaltrials.gov the trial was initially shared on September 28th 2022 and had its most recent update three days later. It is now recruiting 1000 patients from one major centre."
What is the utmost number of individuals participating in this investigation?
"Affirmative. According to the data provided on clinicaltrials.gov, this research is presently seeking volunteers; it was initially posted on September 28th 2022 and recently updated October 3rd 2022. This investigation demands a total of 1000 participants from one location."
What aim is this clinical trial hoping to accomplish?
"The primary outcome of the trial, which will be observed over a period of one year on average, is to measure patient progress with The KnowGene Scale. Secondary outcomes include Provider Time (measured in minutes spent per patient), MICRA (Change in Uncertainty - Score Range = 0-85; Lower score indicates better outcome) and PROMIS scores for Change in General Depression (Score Range = 4-20; again lower indicating improved results)."
Share this study with friends
Copy Link
Messenger